THE DRUG DOCKETThe FDA logged a Class I recall of 4,319 vials of a compounded glutathione injection on 28 October, citing microbial contamination of a product meant to be sterile and sold for injection under the skin.
3 min read
THE DRUG DOCKETAn interim enforcement policy signed by the HHS Secretary lets state-licensed pharmacies and physicians compound from peptide bulk substances on an appendix list while the 503A bulks list is written through rulemaking.
3 min read
WELL CURVETwo real-world cohorts found lower blood levels per milligram from compounded formulations — and the longest longevity trial of rapamycin was run on the weaker one, which changes how to read it.
4 min read
THE DRUG DOCKETIn February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
3 min read
THE DRUG DOCKETThe agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
3 min read